Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Number of shares comprising the share capital
Theoretical number of voting rights
December 31, 2020
*Including 2,355,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on November 19th 2019..
Euronext Growth Paris
ALPHA/FR – Reuters: ALPHA.PA
First day of trading
18 July 2016
Number of shares
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Eligible to PEA-PME (French fiscal advantage)
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Following the “Faces of CMT” photography competition run by HNF, CMTA and ECMTF and supported by Pharnext to mark Rare Disease Day 2021, find the booklet regrouping all photos submitted. Thanks again to all participants!
Find the full recording of Pharnext’s virtual R&D Day: unmet need in Charcot-Marie-Tooth Disease Type 1A, potential for PXT3003, interest of our Pleotherapy platform.
Pharnext will attend the CMT-France Annual Congress, wich is going virtual
Pharnext will attend the 16th International Congress on Neuromuscular Diseases, wich is going virtual over two weekends: 21-22 and 28-29 May
Pharnext will attend the 2021 Annual Meeting of the Peripheral Nerve Society which is going virtual over two weekends in June: 12–13 and 25–27
Pharnext Corporate Presentation - JP Morgan Webcast
Presentation of the R&D Day Event
Highlights of the R&D Day Event
Letter to shareholders
46 Rue Saint-Lazare
75009 Paris, France
+33 (0)1 41 09 22 firstname.lastname@example.org